Louisiana appeals court upholds more than $9 million judgment against Johnson & Johnson
A Louisiana appeals court upheld a judgment exceeding $9 million against Johnson & Johnson after a jury found its talc-based baby powder caused Jeannine Henderson’s mesothelioma and death. The court rejected J&J’s challenges to the jury’s findings and affirmed increased damages for Henderson’s suffering and her sons’ loss.
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
Johnson & Johnson agreed to acquire clinical-stage Ollin Biosciences for $2.2 billion upfront, plus up to approximately $1.125 billion in regulatory and commercial milestones. The deal adds OLN324, a Phase 3 investigational bispecific antibody for retinal diseases including wet AMD and diabetic macular edema. Blackstone Life Sciences will provide $750 million to fund Phase 3 development in exchange for milestones and royalties. The acquisition is expected to close before year-end 2026, subject to regulatory approvals and customary conditions.
Johnson & Johnson raises its 2026 outlook after third-quarter results
Johnson & Johnson reported 5.9% third-quarter sales growth and raised its 2026 outlook to about $101.2 billion in sales and $11.10 adjusted EPS at the midpoint. Innovative Medicine revenue rose 7.7% year over year to $16.76 billion, led by Darzalex, Tremfya, Erleada and newer launches. Growth was partly offset by declining Stelara sales following loss of exclusivity, alongside generic and biosimilar pressure on other products.
Johnson & Johnson presents early clinical data at ASH
Johnson & Johnson presented early clinical results for trispecific antibodies and T cell engagers, plus real-world analyses in multiple myeloma and autoimmune hemolytic anemia, at the 2026 ASH meeting. The data support its oncology and immunology pipeline, which could help offset other business pressures, but do not establish commercial impact. Management plans to discuss sales, free cash flow and EPS targets at its December 8 enterprise review.
Johnson & Johnson leads investment in Francis Medical prostate cancer device
Johnson & Johnson Innovation led a funding round for Francis Medical to advance its Vanquish water-vapor device toward FDA approval for treating localized prostate cancer. The device has 510(k) clearance for prostate tissue ablation but is not FDA-approved to treat cancer. Francis is conducting a 235-patient clinical trial; early results showed benign tissue in 75% of the first 110 patients at six months.
Johnson & Johnson reports second positive Phase 3 study of CAPLYTA for bipolar mania
Johnson & Johnson said CAPLYTA met primary and key secondary endpoints in its second pivotal Phase 3 study for bipolar I mania. The drug improved mania symptoms versus placebo by Week 3, with benefits appearing by Day 3; response rates were 43.9% versus 23.7%. Safety was consistent with prior studies. Together with the first positive Phase 3 study, results support a planned U.S. FDA submission.
Johnson & Johnson sees a path to double-digit growth by 2030
Johnson & Johnson reported 7.4% sales growth in the first nine months of the year, or about 12.2% excluding declining Stelara sales, and sees a path to double-digit growth by 2030. New drugs—including Icotyde, Inlexzo, Lazcluze, and Imaavy—each have estimated peak sales potential above $5 billion, while the investigational anticoagulant milvexian and Ottava surgical robot offer additional growth opportunities.
Massachusetts jury awards $3.325 million against Johnson & Johnson in talc case
A Massachusetts jury awarded $3.325 million to the family of Winifred Haddad, finding Johnson & Johnson’s talc-based baby powder defectively designed and inadequately labeled, and its negligence a substantial factor in her mesothelioma. Haddad, who died in 2020, had used the powder for years; the award includes damages, medical expenses and prejudgment interest. The verdict adds to other talc-related litigation losses for J&J.
Commentators debate Johnson & Johnson’s valuation and earnings assumptions
Johnson & Johnson trades at 23.6 times consensus 2026 earnings and 22.7 times 2027 earnings. The 2026 outlook broadly matches management guidance, while analysts expect 6.6% revenue growth and 3.9% profit growth in 2027. Forecasts could prove optimistic if analysts have not fully included $1.36 per share in expected 2027 costs from the Firefly Bio and Cell BioMedicines deals, or if MedTech growth remains weak.
Johnson & Johnson oncology sales rise 16.8% in first nine months
Johnson & Johnson’s oncology sales rose 16.8% operationally to about $22 billion in the first nine months of 2026, led by Darzalex and newer therapies, while declining Imbruvica sales partly offset growth. The company targets more than $50 billion in oncology sales by 2030 and is advancing candidates across blood and solid cancers. Shares have gained 36.2% this year, but trade above industry and historical valuation levels.
Johnson & Johnson says ICOTYDE meets Phase 3 endpoint in psoriatic arthritis
Johnson & Johnson reported Phase 3 ICONIC-PsA 1 results showing once-daily oral icotrokinra achieved a Week 16 ACR20 response in 58% of biologic-naive patients with active psoriatic arthritis, versus 41% on placebo. ACR50 responses were 29% versus 16%, and skin outcomes also favored treatment. Responses increased numerically through Week 24, with safety consistent with the established profile and no new signals.
Johnson & Johnson reports early results for prostate cancer combination therapy
Johnson & Johnson reported Phase 1 results for its investigational pasritamig and JNJ-9401 combination in advanced prostate cancer. At the recommended regimen, 11 of 15 patients had PSA reductions of at least 50%, including seven with reductions of at least 90%; all seven remained on treatment beyond six months without progression. No Grade 3 or higher treatment-related adverse events were reported, and the regimen is being studied in an ongoing Phase 3 trial.
Johnson & Johnson leads $100 million investment in Delix Therapeutics
Johnson & Johnson’s venture arm is leading a $100 million investment in Delix Therapeutics, which is developing zalsupindole, a psychedelic-inspired depression pill intended to work without hallucinations. Early results in 18 patients showed a roughly 50% reduction in symptoms, but larger controlled trials are needed. Delix plans to start a 240-patient mid-stage trial in 2027, with results expected in 2028.
Johnson & Johnson reports Phase 2 patient findings for nipocalimab in Sjögren’s disease
Johnson & Johnson reported Phase 2 DAHLIAS patient interviews identifying mouth dryness as the symptom patients most wanted improved, followed by eye dryness, fatigue and joint pain. Interviews also indicated that symptom improvements were associated with better daily functioning; 73.5% of participants were satisfied or very satisfied with treatment. Previously reported results found at least a 50% increase in saliva production in 33% of patients receiving high-dose nipocalimab versus 16% on placebo.
FDA approves Johnson & Johnson’s RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval to Johnson & Johnson’s RYBREVANT FASPRO as a single-agent treatment for adults with recurrent or metastatic head and neck squamous cell carcinoma that progresses after platinum chemotherapy and anti–PD-(L)1 therapy; HPV-associated oropharyngeal cancer is excluded. Approval was based on the Phase 1b/2 OrigAMI-4 trial, which showed a 42% confirmed response rate, including 15% complete responses.
Zacks rates J&J shares Sell as earnings estimates decline
Johnson & Johnson shares gained 7% over the past month, outperforming the S&P 500, while its industry rose 13.3%. Zacks reports falling earnings estimates: consensus EPS estimates declined 0.9% for the current quarter, 2.7% for the current year, and 7.7% for next year. J&J is rated Zacks Rank #4 (Sell), with a D valuation grade indicating a premium to peers.
Johnson & Johnson reports lower mortality in Impella analyses
Johnson & Johnson reported three observational analyses of Impella-supported high-risk PCI, with mortality outcomes numerically lower than those reported in the CHIP-BCIS3 study. The data cover 1,379 patients and highlight patient selection, timing and duration of device support, and post-procedure care as factors that may affect outcomes. J&J plans to present the analyses at TCT 2026 and expects results from its randomized PROTECT IV trial in 2027.
Johnson & Johnson’s Javelin catheter meets both study goals
J&J said its investigational Javelin catheter met both primary goals in a 158-patient study, but it still needs FDA review and the trial had no comparison arm. New observational Impella analyses showed lower mortality than estimates from the negative CHIP-BCIS3 trial, but cannot establish that the pump caused better outcomes. A larger randomized trial, PROTECT IV, is expected to report in 2027.
Johnson & Johnson shifts JLabs toward targeted and virtual support
J&J says its JLabs incubator has supported about 1,200 companies since 2012, with more than 500 collaborations and nearly 60% of active on-strategy portfolio companies in deals or discussions. J&J is shifting toward targeted, milestone-based support and virtual incubation while reducing its physical footprint, including closing several locations. It aims to increase engagement with incubated companies and source science globally.
Impella data supports Johnson & Johnson shares as valuation views differ
New TCT analyses linked Johnson & Johnson’s Impella heart pumps to lower mortality in high-risk coronary procedures, supporting recent share gains. J&J shares are up 31.76% year to date, but valuation views conflict: a popular narrative estimates fair value at $240.69 versus a recent price of $273.20, while a market-based comparison finds the stock below its fair P/E ratio and peer average but far above the broader pharmaceutical sector.